|
|
Volumn 11, Issue 1, 2004, Pages 80-86
|
|
Biotech blockbuster forecasts to 2008
a
|
|
Author keywords
Monoclonal antibodies; Therapeutic proteins
|
|
Indexed keywords
ANTIBODIES;
DNA;
FORECASTING;
IMMUNOLOGY;
PROTEINS;
SALES;
BIOLOGICAL BRANDS;
BIOPHARMA SECTOR;
DATAMONITOR ANALYSIS;
BIOTECHNOLOGY;
ADALIMUMAB;
BETA1A INTERFERON;
BEVACIZUMAB;
ETANERCEPT;
INFLIXIMAB;
INSULIN;
INSULIN GLARGINE;
NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;
PALIVIZUMAB;
PEG INTRON A FRANCHISE;
PEGINTERFERON ALPHA2A;
RECOMBINANT ERYTHROPOIETIN;
RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;
RITUXIMAB;
TRASTUZUMAB;
ARTHRITIS;
ARTICLE;
BIOTECHNOLOGY;
DRUG MARKETING;
FORECASTING;
HEMATOLOGY;
IMMUNOPATHOLOGY;
INFLAMMATION;
ONCOLOGY;
PROFESSIONAL STANDARD;
UNITED STATES;
|
|
EID: 7944238355
PISSN: 14628732
EISSN: None
Source Type: Journal
DOI: 10.1057/palgrave.jcb.3040104 Document Type: Article |
|
Times cited : (3)
|
|
References (0)
|
